

PharmLabs San Diego Certificate of Analysis

Sample **Loopy THCA 3G Disposable**

Delta9 THC **UI**

THCa **2.11%**

Total THC (THCa * 0.877 + THC) **1.85%**

Delta8 THC **64.40%**



Sample ID	SD240625-025 (95725)	Matrix	Concentrate (Inhalable Cannabis Good)
Tested for	Nice Leaf Hemp		
Sampled	-	Received	Jun 24, 2024
Analyses executed	CANX	Reported	Jun 26, 2024
		Unit Mass (g)	3.0

Laboratory note: The Δ9-THC results in this particular sample is inconclusive due to potential interferences from several cannabinoids when analyzed using our GC MS/MS D9C method. As a result, this sample will not undergo testing via the GC MS/MS D9C method. However, there are currently no interferences detected with any other cannabinoids in this sample when employing HPLC.

CANX - Cannabinoids Analysis

Analyzed Jun 26, 2024 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoid analysis is approximately **±7.806%** at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabinavin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabidiolcin (CBDO)	0.002	0.007	ND	ND	ND
Abnormal Cannabidiolcin (a-CBDO)	0.01	0.031	ND	ND	ND
(+/-)-9B-Hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.007	0.021	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.001	0.16	ND	ND	ND
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND	ND
Cannabigerol (CBG)	0.001	0.16	ND	ND	ND
Cannabidiol (CBD)	0.001	0.16	ND	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.013	0.041	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.025	0.075	ND	ND	ND
Tetrahydrocannabinavin (THCV)	0.001	0.16	ND	ND	ND
Δ8-tetrahydrocannabinavin (Δ8-THCV)	0.021	0.064	0.36	3.65	10.95
Cannabidihexol (CBDH)	0.005	0.16	ND	ND	ND
Tetrahydrocannabinutol (Δ9-THCB)	0.013	0.038	ND	ND	ND
Cannabinol (CBN)	0.001	0.16	1.04	10.37	31.11
Cannabidiaphoral (CBDP)	0.015	0.047	ND	ND	ND
exo-THC (exo-THC)	0.005	0.16	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	64.40	643.98	1931.94
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	2.11	21.09	63.27
Δ9-Tetrahydrocannabinihexol (Δ9-THCH)	0.024	0.071	2.08	20.85	62.55
Cannabinol Acetate (CBNO)	0.014	0.043	ND	ND	ND
Δ9-Tetrahydrocannabiniphoral (Δ9-THCP)	0.017	0.16	1.90	18.97	56.91
Δ8-Tetrahydrocannabiniphoral (Δ8-THCP)	0.041	0.16	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.008	0.025	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			1.85	18.50	55.49
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			66.25	662.48	1987.43
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND
Total Cannabinoids Analyzed			71.63	716.32	2148.95

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
DEA license: RP0611043
ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
Wed, 26 Jun 2024 12:02:00 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



"This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.